Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 18/20 | 0.53 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23772146 | 0.80 | CYP19A1 (0.45) | CYP19A1CYP11B1CYP3A4TSHRCYP11B2 | |
| SCHEMBL1619037 | 0.73 | SMN1; SMN2 (0.55) | CYP19A1CYP2C19 | |
| SCHEMBL10565254 | 0.72 | CYP19A1 (0.65) | CYP19A1CYP11B1CYP3A4 | |
| SCHEMBL4051634 | 0.72 | CYP19A1 (0.44) | CYP19A1CYP11B1CYP3A4TSHRCYP11B2 | |
| SCHEMBL1371558 | 0.69 | — | — | |
| SCHEMBL9367742 | 0.69 | CYP19A1 (0.61) | CYP19A1CYP11B1CYP3A4 | |
| SCHEMBL11228301 | 0.69 | CYP19A1 (0.67) | CYP19A1CYP11B1CYP3A4TSHRCYP11B2 | |
| SCHEMBL14414182 | 0.69 | CYP19A1 (0.68) | CYP19A1CYP11B1CYP3A4TSHRCYP11B2 | |
| SCHEMBL9913662 | 0.69 | CYP19A1 (0.68) | CYP19A1CYP11B1CYP3A4TSHRCYP11B2 | |
| SCHEMBL10022380 | 0.69 | CYP19A1 (0.61) | CYP19A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11679093-B2 | 2-naphthimidamides, analogues thereof, and methods of treatment using same | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2023-06-20 | — | — | US | disclosed |
| US-20210251942-A1 | 2-NAPHTHIMIDAMIDES, ANALOGUES THEREOF, AND METHODS OF TREATMENT USING SAME | UNIV COLORADO REGENTS (US) | 2021-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11679093-B2 | 2-naphthimidamides, analogues thereof, and methods of treatment using same | TMPRSS2, TMPRSS4, TMPRSS15 | CYP19A1 3866/4885CYP11B1 4395/4885CYP3A4 2284/4885 |
| US-20210251942-A1 | 2-NAPHTHIMIDAMIDES, ANALOGUES THEREOF, AND METHODS OF TREATMENT USING SAME | TMPRSS2, TMPRSS4, TMPRSS15 | CYP19A1 3866/4885CYP11B1 4395/4885CYP3A4 2284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.